B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis
- Antoine François1,
- Emmanuel Chatelus2,
- Dominique Wachsmann1,
- Jean Sibilia1, 2,
- Seiamak Bahram1,
- Ghada Alsaleh†1 and
- Jacques-Eric Gottenberg†1, 2Email author
© François et al.; licensee BioMed Central Ltd. 2013
Received: 22 February 2013
Accepted: 27 September 2013
Published: 28 October 2013
B lymphocytes might play a pathogenic role in dermal fibrosis in systemic sclerosis (SSc). B-cell activating factor (BAFF), a key cytokine for B-cell activation, is increased in the serum and the skin of patients with SSc. However, the ability of B cells directly to stimulate dermal fibroblasts and the role of BAFF are not fully understood. We therefore investigated the involvement of B cells and BAFF in the expression of collagen and profibrotic markers by dermal fibroblasts.
Cocultures of blood B cells from healthy blood donors and normal or SSc dermal fibroblasts stimulated with anti-IgM and BAFF were performed. Alpha-SMA, TIMP1, MMP9, COL1A1, COL1A2, and COL3A1 mRNA expression were determined by quantitative RT-PCR. Soluble collagen, BAFF, IL-6, IL-1β, TGF-β1, and CCL2 protein secretion were assessed.
Coculture of blood B cells and dermal fibroblasts isolated from SSc patients induced IL-6, TGF-β1, CCL2, and collagen secretion, as well as Alpha-SMA, TIMP1, and MMP9 expression in dermal fibroblasts. Transwell assays demonstrated that this induction was dependent on cell-cell contact. Addition of anti-IgM and BAFF to the coculture increased IL-6, CCL2, TGF-β1, and collagen secretion. B cell- and BAFF-induced collagen secretion was highly reduced by anti-TGF-β1 antibodies.
Our results showed for the first time a direct role of B cells on the production of collagen by dermal fibroblasts, which is further enhanced by BAFF. Thus, these results demonstrate a new pathogenic role of B cells and BAFF in fibrosis and systemic sclerosis.
Systemic sclerosis (SSc) is a systemic autoimmune disease that has a complex pathogenesis involving genetic and environmental factors [1, 2]. SSc is characterized by vascular hyperreactivity, skin and visceral organs fibrosis, and immunologic alterations, including production of autoantibodies . Fibrosis results from excessive collagen production by fibroblasts, and recent studies uncovered that B cells might play a role in the development of fibrosis. It was demonstrated that B cell-deficient mice treated with CC14 to trigger hepatic fibrosis showed a reduced collagen deposition by a mechanism dependent on antibodies but independent of T cells . Likewise, CD19-deficient mice exhibit a reduced susceptibility to pulmonary fibrosis after bleomycin challenge, whereas CD19 overexpression exacerbates fibrosis . SSc patients also have B-cells abnormalities such as the production of specific autoantibodies. Moreover, the presence of CD20+ B cells and immunoglobulin genes were detected in skin biopsies of SSc patients [6, 7]. B cells are a source of IL-6 and TGF-β1, which have been shown to regulate collagen synthesis by fibroblasts . In SSc patients, IL-6 serum levels correlate with skin fibrosis, and IL-6-deficient mice have attenuated collagen deposition in lungs after bleomycin challenge [9, 10]. TGF-β1 also has the ability to inhibit collagen degradation by decreasing matrix metalloproteinases (MMPs) and increasing tissue inhibitor of metalloproteinases (TIMPs) expression .
Survival of peripheral B cells is crucially dependent on B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) . The finding that BAFF-transgenic mice develop autoimmune manifestations with similarities to systemic lupus erythematosus and Sjögren syndrome in humans suggested a critical role of BAFF in autoimmune diseases [13, 14]. Elevated levels of BAFF have been detected in serum and skin samples from patients with SSc, which suggests that this cytokine contributes to B-cell abnormalities and disease development in patients with SSc [15, 16].
The pathogenic role of B cells and BAFF in SSc might not be restricted to secretion of immunoglobulins, antigen presentation, or cytokine secretion. However, to date, no study addressed the ability of B cells to stimulate fibroblasts directly. To investigate the involvement of B cells in dermal fibrosis, we used a coculture model of human dermal fibroblasts (HDFs) isolated from healthy controls or SSc patients with blood B cells and assessed collagen and profibrotic cytokine and markers expression. The present study demonstrates that B cells and BAFF are capable of stimulating collagen secretion by dermal fibroblasts.
Patients and cells
Primary cultures of human dermal fibroblasts (HDFs) were established by outgrowth of cells from explanted tissue pieces. Skin biopsies were obtained by punch biopsies from three healthy subjects (NHDF) and from six patients with SSc (SScHDF) of the Departement de Rhumatologie, Hôpitaux Universitaires de Strasbourg, France. Blood mononuclear cells were isolated from six healthy blood donors. Approval by the ethical committee of the Hopitaux Universitaires de Strasbourg was obtained. Informed consent was obtained from patients and healthy donors.
Diagnosis of SSc was performed according to the revised criteria of the American College of Rheumatology (ACR). All patients were female and had diffuse cutaneous systemic sclerosis and anti-Scl70-positive antibodies. All biopsies were isolated from the forearm of SSc patients. The modified Rodnan skin scores were 29, 8, 0, 25, 28, and 14, respectively. Two patients were treated with oral prednisone (Cortancyl) (5 or 10 mg/day, respectively), and one patient was treated with methotrexate (10 mg/week). Three patients were treated with both oral prednisone and methotrexate. HDFs were used in the experiments between the third and the sixth passages. Blood mononuclear cells were isolated from healthy blood donors by Ficoll-Paque centrifugation, as described in standard protocols. B cells were then selected by negative sorting by using EasySep Human B Cell Enrichment Kit (Stemcell Technologies Grenoble, France). The efficacy of B-cell isolation was determined with FACS analysis by using anti-CD19 antibodies. The yield of isolated B cells was composed of 99% CD19+/CD3- B cells, 0.01% of CD19-/CD3+ T cells, and 0.09% of CD19-/CD3- cells.
Cultures and reagents
Cells were cultured in RPMI1640 supplemented with fetal calf serum (FCS), penicillin, streptomycin, amphotericin B (all from Invitrogen). HDF (105 cells) alone, B cells (3 × 105 or 5 × 105 cells) alone, or cocultures were seeded in 24-well plates for 3 or 5 days. For transwell experiments, B cells (5 × 105 cells) and HDF (105 cells) were seeded in the upper and lower chambers, respectively, of a 0.4-μm polycarbonate membrane transwell (Nunc Dominique Dutscher, Brumath, France). For fibroblasts stimulation, cells were incubated with 5 ng/ml of recombinant TGF-β1 (from R&D Systems Lille, France). For B-cell stimulation, cells were incubated with 100 ng/ml of soluble recombinant human BAFF (rhBAFF; R&D systems Lille, France) in the presence of 5 μg/ml goat F(ab′)2 anti-human μ-chain Ab (Jackson ImmunoResearch Laboratories Suffolk, UK) . Anti-LAP-TGF-β1 (AF-246-NA), anti-IL-6 (Clone 6708), anti-integrin α4/VLA4/CD49d (Very Late Antigen-4, Clone 2B4), or control IgG (all from R&D Systems Lille, France) were incubated at 20 μg/ml, unless specified in the figure legends.
Real-time quantitative RT-PCR
in which ΔCt (change in cycle threshold) is the cycle threshold of the test gene minus the cycle threshold of GAPDH, Ct2 is a specific sample, and Ct1 is the control sample. The primers used are GAPDH forward (5′- GGTGAAGGTCGGAGTCAACGGA-3′) and reverse (5′-GAGGGATCTCGCTCCTGGAAGA-3′); COL1A1 forward (5′-CACACGTCTCGGTCATGGTA-3′) and reverse (5′-CGGCTCCTGCTCCTCTTAG-3′); COL1A2 forward (5′-AGCAGGTCCTTGGAAACCTT-3′) and reverse (5′-GAAAAGGAGTTGGACTTGGC-3′); COL3A1 forward (5′-ATATTTGGCATGGTTCTGGC-3′) and reverse (5′-TGGCTACTTCTCGCTCT GCT-3′); ACTA2 (α-SMA) forward (5′-GATGGCCACTGCCGCATCCT-3′) and reverse (5′-ACAGGGTCTCTGGGCAGCGG-3′); MMP9 forward (5′-TTGGTCCACCTGGTTCAACT-3′) and reverse (5′-ACGACGTCTTCCAGTACCGA-3′); TIMP1 forward (5′-TTGACTTCTGGTGTCCCCAC-3′) and reverse (5′-CTGTTGTTGCTGTGGCTGAT-3′); BAFF-R (TNFRSF13C) forward (5′-GATTCCCGGAGACAGAATGA-3′) and reverse (5′-GTGGGTC TGGTGAGCTGG-3′); TACI (TNFRSF13B) forward (5′-ATCCCAGTACTGCTCTTCGG-3′) and reverse (5′-CTGAGTAATGAGTGGCCTGG-3′); BCMA (TNFRSF17) forward (5′-CAG TCCTGCTCTTTTCCAGG-3′) and reverse (5′-TGGCAGTTTTCGTGCTAATG-3′).
Enzyme-linked immunosorbent assay
Human BAFF, IL-6, CCL2 (MCP-1), latent and active TGF-β1, and IL-1β were assessed in 3- and 5-day culture supernatants by using a standard ELISA kit according to the manufacturer’s instructions (R&D Systems Lille, France).
Collagen measurements in cell-culture supernatants
Aliquots of supernatant (200 μl) were assayed for collagen levels and compared with a standard curve prepared from bovine skin by using the Sircol collagen dye-binding assay, according to the manufacturer’s instructions (Biocolor Ltd. Interchim, Montluçon, France).
B-cell viability assay
B cells alone or cocultured with fibroblasts were seeded in 24-well plates for 3 or 5 days. For transwell experiments, B cells (5 × 105 cells) and HDF (105 cells) were seeded in the upper and lower chambers, respectively, of a 0.4-μm polycarbonate membrane transwell (Nunc). After 3 or 5 days, B cells were stained with 3,3-dihexyloxacarbocyanine iodide (DiOC6) to assess the mitochondrial transmembrane potential (Ψm), and with propidium iodide (PI) to assess membrane permeability. In brief, cell suspensions were incubated with 40 nM DiOC6 and 1 μg/ml PI for 15 minutes at 37°C, washed with FACS buffer, and then analyzed on FACS Calibur (BD Biosciences Le Pont de Claix, France). A lymphocyte gate was set by using forward-angle and side-angle light-scatter characteristics of lymphocytes. The vital B cells were brightly positive when stained with DiOC6 and excluded PI.
Values were reported as the median ± interquartile range. Two-tailed Mann–Whitney test was used to compare two independent groups by using GraphPad software. A probability (P) value of <0.05 was considered to be significant.
B cells induce the production of collagen by dermal fibroblasts from SSc patients and healthy controls
Coculture of B cells and SScHDFs induces the expression of collagen and profibrotic markers
BAFF upregulates the expression of collagen, α-SMA, and TIMP1 in SScHDF cocultured with B cells
Both cell-cell contact and soluble mediators are involved in collagen and profibrotic markers expression
We then evaluated whether the increased collagen secretion induced by B cells is due to soluble or cell-membrane factors. B cell-induced collagen production by SScHDF was completely inhibited by the use of transwells (Figure 3A,B). In addition, transwells completely abrogated the effect of B cells on α-SMA, TIMP-1, and MMP9 expression in SScHDF (Figure 3C). Conversely, in the presence of anti-IgM and BAFF, collagen production, as well as α-SMA, TIMP-1, and MMP9 expression, were only partially inhibited by transwells (Figure 3A,B,C).
Collectively, these data indicate that B cell-induced collagen secretion by SScHDF is contact dependent, but the effect of BAFF in coculture is, at least partly, dependent on soluble factors.
Involvement of profibrotic cytokines in B cell- and BAFF-induced fibrosis
B cell- and BAFF-induced fibrosis is mediated by TGF-β1
These data indicate that TGF-β1 plays a pivotal role in the promotion of fibrosis induced by B cells and BAFF.
In this study, we demonstrated that B cells cocultivated with human dermal fibroblasts (HDFs) are potent inducers of collagen and profibrotic cytokine production. As fibrosis results from excessive collagen production by fibroblasts, these data support the hypothesis that B cells could play a role in the development of skin fibrosis in SSc. So far, studies on the role of B cells in SSc focused on their ability to secrete autoantibodies, such as anti-DNA topoisomerase I antibodies that may play a pathogenic role. Hénault et al. showed that binding of DNA topoisomerase I to HDF membrane induces monocytes adhesion, in turn activated by anti-topoisomerase I autoantibodies isolated from SSc patients.
Moreover, it is well established that SSc patients show several B-cell abnormalities, such as an overexpression of CD19 as well as a disturbed peripheral homeostasis . SSc patients also show an expansion of naïve B cells and reduced memory B cells and plasmablasts/early plasma cells [21, 22]. We investigated the direct interaction between B cells and dermal fibroblasts. First, we demonstrated that B cells increased collagen secretion by dermal fibroblasts with a magnitude comparable to the stimulation of fibroblasts with recombinant TGF-β1. Conversely, PBMCs did not induce collagen secretion, which might be due to the opposite effect of T lymphocytes. It was reported that T lymphocytes inhibit collagen secretion by dermal fibroblasts via membrane-bound TNF-α [23, 24]. Interestingly, no difference in terms of collagen secretion was observed between fibroblasts of patients with SSc and healthy individuals. This capacity to increase collagen secretion might also be further enhanced in vivo by specific properties of B cells and the local environment observed in the disease. Given that B cells are activated in SSc, it is also possible that SSc B cells could be more-potent inducers of collagen production than normal B cells. This hypothesis could not be tested because the effect of normal B cells on fibroblasts is already so profound that it would be difficult to observe any differences between SSc B cells and normal B cells.
Coculture of B cells with SScHDF induced the secretion of IL-6, CCL2 and TGF-β1, cytokines that are known to stimulate the production of collagen by fibroblasts. Concerning IL-6, our data are consistent with previous observations showing that coculture of a B cell line established from lung tissue of a patient with progressive SSc and normal lung fibroblasts results in the production of high amounts of IL-6 . CCL2 is a potent inflammatory mediator and regulates collagen synthesis, and TGF-β1 is one of the major cytokines implicated in SSc by regulating extracellular matrix (ECM) production, fibroblast proliferation, and differentiation .
We also observed that coculture of B cells with SScHDF promotes the expression of TIMP1 and MMP9, which are implicated in the remodeling of the ECM. TIMP1 and MMP9 are upregulated in the serum of SSc patients and were found to correlate with disease activity [18, 27]. SScHDF cocultured with B cells also expressed higher levels of α-SMA, which is a marker of differentiation of fibroblasts into contractile myofibroblasts. Myofibroblasts are specialized fibroblasts that show features of smooth muscle cell differentiation. They also synthesize collagen and are a major source of TGF-β1 and TIMP-1 during the fibrotic process [28, 29].
Because BAFF is a pivotal cytokine for B-cell activation and its serum level is increased in SSc patients and correlates with the extent of skin fibrosis, we subsequently assessed whether BAFF could amplify B cell-induced fibrosis. First, we showed that BAFF was not secreted by dermal fibroblasts, B cells, or in cocultures. We then added BAFF and anti-IgM antibodies, because in vitro stimulation of B cells with BAFF requires their activation with anti-IgM antibodies . BAFF exacerbated the effect of B cells on collagen production by SScHDF. BAFF also acted as a potent inducer of TIMP-1, α-SMA, CCL2, and IL-6. A similar induction of IL-6 by BAFF was also recently reported in monocytes of patients with primary Sjögren syndrome .
With transwell experiments, we also showed that cytokine release and collagen production are inhibited in the absence of cell-cell contact, indicating that the effect of B cells on SScHDF is related to membrane-bound factor(s). Recently, the interaction α4β1 integrin/VCAM-1 (vascular cell adhesion molecule 1) was identified as responsible for the interaction of blood B cells with skin fibroblasts . By using blocking antibodies against integrin α4/VLA-4/CD49d, we determined that these molecules were not implicated in B cell-induced fibrosis in this model (data not shown). However, blocking TGF-β1 inhibited the effect of BAFF on collagen overproduction, suggesting that TGF-β1 is the key final mediator involved in B cell-induced fibrosis.
This suggests two hypotheses: (a) membrane TGF-β1 is directly implicated in the collaboration between B cells and fibroblasts; and (b) an as yet unknown cell-surface molecule on B cells (adhesion molecule, cytokine) induces TGF-β1 secretion by dermal fibroblasts.
These results reinforce the rationale for targeting B cells and/or BAFF in SSc. Recent open studies on limited populations of patients with SSc reported that B-cell depletion could result in decreased skin thickening [32–34]. This study suggests that BAFF could be an interesting therapeutic target in SSc, by its amplifying effect on profibrotic cytokines and collagen secretion. Interestingly, in the tight-skin mouse model, B-cell depletion or BAFF inhibition prevents skin fibrosis [35, 36].
B cells and BAFF play a pathogenic role in skin fibrosis in SSc by upregulating collagen secretion by dermal fibroblasts in a TGF-β1-dependent manner. Thus, these results demonstrate a new pathogenic role of B cells and BAFF in fibrosis and systemic sclerosis.
α-smooth muscle actin
A proliferation-inducing ligand
B cell-activating factor
Chemokine (C-C motif) ligand 2
Collagen type 1, α 1
Glyceraldehyde 3-phosphate dehydrogenase
Human dermal fibroblasts
Matrix metallopeptidase 9
Peripheral blood mononuclear cell
Transforming growth factor beta 1
Tissue inhibitor of metalloproteinase 1
Vascular cell-adhesion molecule 1
Very late antigen-4.
We thank Angélique Pichot for technical assistance. AF’s work was supported by a grant from the Fondation Groupama pour la santé (Bourse espoir 2009 de la Fondation Groupama pour la santé). This study was supported by grants from the Société Française de Rhumatologie and the Association des Sclérodermiques de France.
- Mouthon L: SSc in 2011: from mechanisms to medicines. Nat Rev Rheumatol. 2012, 8: 72-74.PubMedGoogle Scholar
- Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, Matucci-Cerinic M: The genetics of systemic sclerosis: an update. Clin Exp Rheumatol. 2011, 29: S75-S86.PubMedGoogle Scholar
- LeRoy EC, Medsger TA: Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001, 28: 1573-1576.PubMedGoogle Scholar
- Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A: Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005, 115: 3072-3082. 10.1172/JCI24798.PubMed CentralView ArticlePubMedGoogle Scholar
- Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S: CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum. 2008, 58: 3574-3584. 10.1002/art.23995.View ArticlePubMedGoogle Scholar
- Kraaij MD, van Laar JM: The role of B cells in systemic sclerosis. Biologics. 2008, 2: 389-395.PubMed CentralPubMedGoogle Scholar
- Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA. 2003, 100: 12319-12324. 10.1073/pnas.1635114100.PubMed CentralView ArticlePubMedGoogle Scholar
- Duncan MR, Berman B: Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991, 97: 686-692.View ArticlePubMedGoogle Scholar
- Sato S, Hasegawa M, Takehara K: Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001, 27: 140-146. 10.1016/S0923-1811(01)00128-1.View ArticlePubMedGoogle Scholar
- Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, Yamada W, Shiraishi Y, Hasegawa N, Fujishima S, Takano H, Ishizaka A: Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol. 2008, 38: 566-571. 10.1165/rcmb.2007-0299OC.View ArticlePubMedGoogle Scholar
- Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, Ertault M, Tiev K, Michel L, Mauviel A, Farge D: Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford). 2007, 46: 833-841. 10.1093/rheumatology/kel451.View ArticleGoogle Scholar
- Mackay F, Schneider P: Cracking the BAFF code. Nat Rev Immunol. 2009, 9: 491-502. 10.1038/nri2572.View ArticlePubMedGoogle Scholar
- Kalled SL: The role of BAFF in immune function and implications for autoimmunity. Immunol Rev. 2005, 204: 43-54. 10.1111/j.0105-2896.2005.00219.x.View ArticlePubMedGoogle Scholar
- Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999, 190: 1697-1710. 10.1084/jem.190.11.1697.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, Takehara K, Sato S: Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol. 2007, 34: 2056-2062.PubMedGoogle Scholar
- Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S: Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006, 54: 192-201. 10.1002/art.21526.View ArticlePubMedGoogle Scholar
- Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, Thompson JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kalled SL, Mackay F, Mackay CR: B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004, 173: 807-817.View ArticlePubMedGoogle Scholar
- Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH, Cho CS: Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther. 2005, 7: R71-R79. 10.1186/ar1454.PubMed CentralView ArticlePubMedGoogle Scholar
- Henault J, Robitaille G, Senecal JL, Raymond Y: DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum. 2006, 54: 963-973. 10.1002/art.21646.View ArticlePubMedGoogle Scholar
- Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF: Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol. 2004, 41: 1123-1133. 10.1016/j.molimm.2004.06.025.View ArticlePubMedGoogle Scholar
- Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000, 165: 6635-6643.View ArticlePubMedGoogle Scholar
- Sato S, Fujimoto M, Hasegawa M, Takehara K: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004, 50: 1918-1927. 10.1002/art.20274.View ArticlePubMedGoogle Scholar
- Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM: Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum. 2003, 48: 2593-2604. 10.1002/art.11129.View ArticlePubMedGoogle Scholar
- Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM: Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum. 1998, 41: 2039-2047. 10.1002/1529-0131(199811)41:11<2039::AID-ART20>3.0.CO;2-1.View ArticlePubMedGoogle Scholar
- Kondo K, Okada T, Matsui T, Kato S, Date K, Yoshihara M, Nagata Y, Takagi H, Yoneda M, Sugie I: Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine. 2001, 13: 220-226. 10.1006/cyto.2000.0822.View ArticlePubMedGoogle Scholar
- Abraham DJ, Krieg T, Distler J, Distler O: Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009, 48: iii3-iii7. 10.1093/rheumatology/ken481.View ArticleGoogle Scholar
- Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE: Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud’s phenomenon, and in normal controls. Ann Rheum Dis. 2001, 60: 846-851.PubMed CentralView ArticlePubMedGoogle Scholar
- Varga J, Abraham D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007, 117: 557-567. 10.1172/JCI31139.PubMed CentralView ArticlePubMedGoogle Scholar
- Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD: Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem. 1995, 270: 3423-3428. 10.1074/jbc.270.7.3423.View ArticlePubMedGoogle Scholar
- Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, Tsuzaka K, Ogawa Y, Tsubota K, Abe T, Takeuchi T: Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren’s syndrome. Arthritis Res Ther. 2011, 13: R170-10.1186/ar3493.PubMed CentralView ArticlePubMedGoogle Scholar
- Couture P, Paradis-Massie J, Oualha N, Thibault G: Adhesion and transcellular migration of neutrophils and B lymphocytes on fibroblasts. Exp Cell Res. 2009, 315: 2192-2206. 10.1016/j.yexcr.2009.04.013.View ArticlePubMedGoogle Scholar
- Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010, 12: R54-10.1186/ar2965.PubMed CentralView ArticlePubMedGoogle Scholar
- Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP: Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum. 2010, 40: 127-136. 10.1016/j.semarthrit.2009.09.003.View ArticlePubMedGoogle Scholar
- Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP: Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2011, 30: S17-S22.Google Scholar
- Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006, 169: 954-966. 10.2353/ajpath.2006.060205.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F, Watanabe R, Takehara K, Sato S: BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol. 2007, 127: 2772-2780.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.